Skip to search formSkip to main contentSkip to account menu

eugenosedin-A

Known as: 4-(2-hydroxy-3-(1-(2-chlorophenyl)piperazinyl))propoxy(-3-methoxy-1-propylenylbenzene) 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Piperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Eugenosedin‐A ameliorates hyperlipidemia‐induced vascular endothelial dysfunction via inhibition of α1‐adrenoceptor/5‐HT activity and NADPH oxidase expression
2012
2012
Eugenosedin‐A prevents high‐fat diet increased adhesion molecules through inhibition of MAPK‐ and p65‐mediated NF‐κB pathway in rat model
Previous studies have shown eugenosedin‐A, a 5‐HT1B/2A and α1/α2/β1‐adrenergic blocker, is able to decrease cholesterol levels… 
2011
2011
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin‐A
Objectives  Eugenosedin‐A has been found to ameliorate high‐fat diet (HFD)‐induced hyperglycaemia and hyperlipidaemia in C57BL/6J… 
2007
2007
Eugenosedin‐A amelioration of lipopolysaccharide‐induced up‐regulation of p38 MAPK, inducible nitric oxide synthase and cyclooxygenase‐2
In this study, we investigate the protective effects of eugenosedin‐A on p38 mitogen‐activated protein kinase (MAPK… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)